Navigation Links
Cholesterol Drug Fails to Slow Progression of Coronary Disease,,Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinic researchers today report that the drug torcetrapib, despite raising high density lipoprotein cholesterol (HDL) or the "good" cholesterol by more than 60%, did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe.

Steven Nissen, M.D., Chairman of Cardiovascular Medicine at Cleveland Clinic and lead investigator of this clinical trial, will present the study on Monday, March 26 at 8:30 a.m. at the of Cardiology's (ACC) 56th Annual Scientific Session. Dr. Nissen is also President of the ACC. The study will be simultaneously published in the New England Journal of Medicine.

All development of this drug was terminated on Dec. 2, 2006 after the safety board monitoring a separate large clinical outcomes trial reported that torcetrapib increased the risk of death and other adverse cardiovascular outcomes.

"We found that the torcetrabip/atorvastatin combination markedly increased good cholesterol levels and lowered bad cholesterol in patients. Unfortunately this drug also substantially raised blood pressure and failed to slow the buildup of plaque," Dr. Nissen said. "It is yet to be determined of this failure represents a problem unique to torcetrapib or predicts a lack of efficacy for the entire class of similar drugs. These findings further demonstrate the great difficulty in developing therapies to disrupt the atherosclerotic disease process."

The development of drugs to raise HDL has been a key research priority because, despite lowering LDL (low-density lipoprotein, or "bad") cholesterol with statin drugs, many patients continue to experience heart attacks, stroke or sudden cardiac death.

A total of 1,188 coronary artery disease patients were enrolled in the "Investigation of Lipid Level management using coronary UltraSound To assess Reduction of Atherosclerosis by CET
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
4. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
5. CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
6. CSL Therapy That Mimics Good Cholesterol May Reduce Plaque Volume in Coronary Arteries
7. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
8. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
9. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
Post Your Comments:
(Date:12/1/2008)... ROCKVILLE, Md., Dec. 1 ...rts publication in The Lancet , one of the world,...ials of its novel circadian regulator, experimenta... by Rajaratnam et al(1) is entitled "Melatonin ago...after sleep-time shift: two randomised controlled ...
(Date:12/1/2008)... St. Jude study shows the Prox1 gene is a two-way...thelial cells to be reprogrammed so that they lose...lial cells , , MEMPHIS, Tenn., Dec. 1 /PRNe...dren,s Research Hospital have discovered that a ce...ge its identity that it requires the constant expr...
(Date:12/1/2008)... ATLANTA, Dec. 1 GeoVax...a-based biotechnology company developing,human va...eficiency Virus) and,other infectious agents, ann...,Vaccine Trials will take place in twelve sites a...onducted in collaboration with The National Instit...
(Date:11/28/2008)... INDIANAPOLIS, Nov. 28 ...n its supplemental New Drug Application (sNDA) fro... Cymbalta(R) (duloxetine HCl),for the management ...cation in,the first half of 2009, adding data fro...osteoarthritis pain of the knee. , The deci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 1UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 2UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 3UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 1NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 2NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 3NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 5Shape Shifting on Veterans Day 5756 1Shape Shifting on Veterans Day 5756 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 1More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 3More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 4
...LE, Calif., April 16, 2007 /PRNewswire-FirstCall/ ...anism of action of,its anti-cancer agent BZL101, w...r late stage breast cancer at the American,Associa...os Angeles,Convention Center in Los Angeles, CA, A...n will describe the pathway for,cancer cell apopto...
...agonist Demonstrates Clinical Activity, a Novel Me...other HCV Inhibitors-, NEW HAVEN, Conn., April 16,...uticals, Inc. today announced the presentation of,... one of,Achillion,s NS4A antagonists, ACH-806, for...n at the 42nd Annual Meeting of the,European Assoc...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:12/2/2008)...stCall/ -- Genoptix, Inc. (Nasdaq: GXDX ), a spe...nced the Company,s participation at the RBC Capita...take place at the Westin New York Hotel at Times S...ccitelli, COO and executive vice president of Geno...conference on Wednesday, December 10, beginning at...
(Date:12/2/2008).../ -- LCA-Vision Inc. (Nasdaq:, LCAV ), a leading...r the,LasikPlus(R) brand, today announced that me...nt at RBC Capital Markets, 2008 Healthcare Confere...astern time. The conference is,being held at The... archived,webcast of the event will be available ...
(Date:12/2/2008)... -- In response to the commentary entitled "Cod Li...Infections, and the Vitamin D Deficiency Epidemic"...ement experts, Nordic Naturals announced today tha...promise to consumers and actually offer healthy om...itamin A. According to Karin Yien, MD, Nordic Natu...
(Date:12/2/2008)...hcare group at Frost & Sullivan,( http://www....t it will be,hosting an interactive analyst brief... on 11 December 2008 at 3pm GMT. , (Logo: ...O ) , With most diagnostic cardiology marke...are faced with an immense challenge of keeping pro...
Breaking Medicine News(10 mins):Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2
...in Andhra Pradesh have hit on a novel method of pr...n thousands of residents opened their// newspapers...three condoms on the front page. "Earlier we dist..., through milk vendors and at pan (tobacco) shops ...
...ticals, a leading player in the Indian drug indust...d and Drug Authority (FDA) for three// of its abbr...me. Orchid will be launching this product in the... partner, Apotex, the Chennai-based company said i...
...ts are high in saturated and trans fats, a high in...ed rate of decline in thinking, learning// and mem... essential for brain development and function, an ...ole in the development of brain plaques associated...
...British Medical Journal, researchers at Oxford Uni...er cent in the consumption of common foods// conta...increase in coronary heart disease. Trans fats ar...shelf life of food and is added to most fast foods...
Other Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
...es BchiVac V-500 with Vacuum Controller V-800 Ef... switching mechanism turns V-500 on and off as nee...ing Model V-500 is a powerful PTFE membrane vacu...s. Applications Ideally suited for use with up ...
...1000 is a new addition to the powerful PTFE membra...ce pump can achieve an ultimate vacuum of 1 mbar o... with vacuum drying ovens and centrifugal vacuum c...size up to industrial size rotary evaporators Bchi...
...500 is a powerful PTFE membrane vacuum pump design...ns Ideally suited for use with up to two rotary ...ents including vacuum ovens, concentrators, gel dr...es PEEK head resistant to chemicals and heat load...
Medicine Products: